Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study

被引：0
|
作者：
Peng, Peijian
Xu, Xiaolu
Zhong, Jincai
Lin, Hong
Wang, Hong
Ye, Jin-Hui
Du, Caiwen
Wang, Zhi-Hui
Yu, Gengsheng
Zou, Guorong
Ouyang, Jie
Wang, Yong-Xia
Li, Lu-Zhen
Xu, Fei
Cui, Shi-En
机构：
[1] Sun Yet Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] Zhuhai Hosp Integrated Tradit Chinese & Western M, Zhuhai, Peoples R China
[4] Zhuhai Matern & Child Hlth Hosp, Dept Breast Surg, Zhuhai, Peoples R China
[5] First Peoples Hosp Zhaoqing, Zhaoqing, Peoples R China
[6] Chinese Acad Med Sci, Shenzhen Ctr, Canc Hosp, Dept Med Oncol, Shenzhen, Longgang Distri, Peoples R China
[7] Jiangmen Cent Hosp, Jiangmen, Peoples R China
[8] Panyu Cent Hosp, Guangzhou, Peoples R China
[9] Dongguan Winter Melon Hosp, Dongguan, Peoples R China
[10] Dongguan Peoples Hosp, Dongguan, Peoples R China
[11] Guangzhou Univ Tradit Chinese Med, Zhongshan Hosp Tradit Chinese Med, Zhongshan City, Peoples R China
[12] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[13] Zhongshan City Peoples Hosp, Dept Gen Surg, Zhongshan City, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13102
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
    Choi, Jin Ho
    Lee, Hee Seung
    Huh, Gunn
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
  • [42] Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
    Kenichi Inoue
    Jun Ninomiya
    Tsuyoshi Saito
    Katsuhiko Okubo
    Takashi Nakakuma
    Hirofumi Yamada
    Kei Kimizuka
    Tohru Higuchi
    Investigational New Drugs, 2019, 37 : 592 - 593
  • [43] A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
    Wuelfing, Christian
    Machiels, Jean-Pascal H.
    Richel, Dirk J.
    Grimm, Marc-Oliver
    Treiber, Uwe
    De Groot, Marco R.
    Beuzeboc, Philippe
    Parikh, Roma
    Petavy, Frank
    El-Hariry, Iman A.
    CANCER, 2009, 115 (13) : 2881 - 2890
  • [44] Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study
    Rossi, E
    Perrone, F
    Labonia, V
    Landi, G
    Nuzzo, F
    Amabile, G
    Gridelli, C
    Di Maio, M
    D'Aiuto, G
    de Matteis, A
    ONCOLOGY, 2003, 64 (04) : 479 - 480
  • [45] Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC)
    Kehmann, Linde
    Berres, Marie
    Gonzalez-Carmona, Maria A.
    Modest, Dominik Paul
    Mohr, Raphael
    Wree, Alexander
    Venerito, Marino
    Strassburg, Christian
    Keitel, Verena
    Trautwein, Christian
    Luedde, Tom
    Roderburg, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: An open-label, phase II dose-confirmation study
    Savulsky, C.
    Twelves, C.
    Anthoney, A.
    Yin, S.
    Evans, T. R. J.
    Oncology Research and Treatment, 2015, 38 : 253 - 253
  • [47] Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase II dose-confirmation study
    Twelves, Chris
    Nasim, Muhammad Y.
    Anthoney, Alan
    Savulsky, Claudio I.
    Yin, Shuxin
    Evans, T. R. Jeffry
    CANCER RESEARCH, 2015, 75
  • [48] Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer
    Han, H.
    Hamilton, E.
    Irie, H.
    Isakoff, S.
    Jelovac, D.
    Liem, A.
    Liu, M. C.
    Milillo, A.
    Nangia, J.
    Page, D.
    Reeves, J.
    Santa-Maria, C.
    Duncan, M.
    Graham, J. R.
    Chen, J.
    Dezube, B. J.
    Spring, L.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] A phase II open-label trial to evaluate the efficacy and toxicity of erlotinib in women with metastatic, hormone receptor negative, and HER2-negative breast cancer
    Rao, R. D.
    Siziopikou, K. P.
    Cobleigh, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [50] Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
    Huh, Gunn
    Lee, Hee Seung
    Choi, Jin Ho
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
12345